Bio Pharma Dive
JANUARY 31, 2025
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?
Pharmaceutical Technology
JANUARY 31, 2025
The FDA has approved Vertex Pharmaceuticals oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JANUARY 31, 2025
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.
Pharmaceutical Technology
JANUARY 31, 2025
Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching 880m ($833m).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JANUARY 31, 2025
Tazbaz was director of the FDA’s Digital Health Center of Excellence for two years, leading on policies involving artificial intelligence and software as a medical device.
Pharmaceutical Technology
JANUARY 31, 2025
Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JANUARY 31, 2025
The CDMO has not disclosed how many employees will be affected by the operational wind down.
Medical Xpress
JANUARY 31, 2025
New research from the University of Minnesota shows that death rates for early adults, or adults aged 2544, rose sharply during the COVID-19 pandemic and remain higher than expected post-pandemic.
Pharmaceutical Technology
JANUARY 31, 2025
On 1 January 2025, important legal amendments relating to drug pricing in Germany included in the Medical Research Act came into legal force.
Medical Xpress
JANUARY 31, 2025
A new study from the University of Chicago Medicine reveals that people with alcohol use disorder (AUD) and depression experience high levels of stimulation and pleasure when intoxicated, similar to drinkers who do not have depression.
Pharmaceutical Technology
JANUARY 31, 2025
CRISPR-based gene therapy Casgevy has been made available to patients with sickle cell disease in England.
pharmaphorum
JANUARY 31, 2025
In a shock move, AstraZeneca has ditched its plan to invest 450m in a new vaccine manufacturing plant in the UK.
Pharmaceutical Technology
JANUARY 31, 2025
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various factors.
pharmaphorum
JANUARY 31, 2025
Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JANUARY 31, 2025
Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.
pharmaphorum
JANUARY 31, 2025
Recent financings in the digital health and AI space include rounds for Rad AI, Eleos, Allara Health, Manas AI, Delfina Care, and Grey Matter Neuro
Medical Xpress
JANUARY 31, 2025
A recent study carried out by a research team from the Paul-Ehrlich-Institut investigated the immunomodulating properties of -glucans. These are natural sugar compounds found in bacteria, fungi and grains. The results indicate that -glucans can target the immune system and modulate pro-inflammatory responses. Their potential to suppress allergic reactions and offer new approaches to allergy treatment is particularly promising.
pharmaphorum
JANUARY 31, 2025
Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.
Medical Xpress
JANUARY 31, 2025
University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage. If approved, the new drug may be tolerated by a broader range of leukemia patients and even be used to treat other cancers.
XTalks
JANUARY 31, 2025
The FDA has approved Journavx (suzetrigine) , a first-in-class, non-opioid treatment for adults experiencing moderate-to-severe acute pain. As an oral, selective NaV1.8 pain signal inhibitor, Journavx blocks pain at the source while avoiding the addictive risks associated with opioids. Journavx will be priced at $15.50 per 50mg pill , making it a competitively priced option in the non-opioid pain management market.
Medical Xpress
JANUARY 31, 2025
Brain injuries are a leading cause of death and long-term disability in infants. Among the most common is neonatal hypoxic-ischemic encephalopathy (HIE), which affects one to three in 1,000 live births per year and accounts for 22% of infant deaths worldwide. Only slightly less common is perinatal arterial ischemic stroke (PAIS).
Pharmaceutical Commerce
JANUARY 31, 2025
Celltrions Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19in the same dosages and formulations as its tocilizumab reference product.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Medical Xpress
JANUARY 31, 2025
Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.
pharmaphorum
JANUARY 31, 2025
Watch the exclusive interview with Steve Pakola during the JP Morgan Week 2025 as he shares insights and updates on the latest trends and developments in the industry.
Medical Xpress
JANUARY 31, 2025
A team of international researchers led by scientists at City of Hope have demonstrated a way to boost thymic function after damage in preclinical studies. The team's study results, published today in the journal Immunity, outline their discovery of a specific type of regulatory T cell that can home back into the thymus and repair the organ when it's damaged.
pharmaphorum
JANUARY 31, 2025
Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Medical Xpress
JANUARY 31, 2025
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Pharmaceutical Commerce
JANUARY 31, 2025
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld value & access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his upcoming February column.
Medical Xpress
JANUARY 31, 2025
Research from Saint Louis University (SLU) and the University of Nevada, Reno School of Medicine finds that some of the most-watched ads promote the worst food options for adults with chronic health conditions.
Pharmaceutical Commerce
JANUARY 31, 2025
The latest news for pharma industry insiders.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
321 
Let's personalize your content